The objective of the current study was to determine whether magnetic resonance imaging (MRI) could be successfully utilized to document the effect of an oestrogenic anabolic agent on pituitary gland growth. The experimental animals consisted of two 1/2 sibling Suffolk wethers (castrated rams), which received either no implant (control, n ¼ 1) or a 24 mg zeranol implant at day 0 and day 42 (zeranol; n ¼ 1). Animals were anaesthetized with propofol and supported with oxygen during the MRI procedure. A mobile MRI unit with a 0.5 tesla (T), superconducting magnet was used to obtain 3 mm thick, non-contrast enhanced, T1-weighted (TR 500-600, TE25) sagittal, transverse and dorsal images of the pituitary gland. Sagittal images were recorded only when the mesencephalic aqueduct and infundibulum were distinctly visible in the same image. Pituitary glands were imaged at 14-day intervals for 70 days to determine if and when the anabolic effects of zeranol on pituitary gland growth could be visualized using MRI techniques. Three separate measurements of the pituitary gland dimensions made with the on-screen cursor were averaged to calculate pituitary gland dimensions and volume. A computer-assisted image analysis system and laser film images were used to determine pituitary gland area. Increases in pituitary gland volume for control and zeranol-treated animals were evident within 14 days, and by the end of the 70-day study, the increase in pituitary volume for the zeranol-treated animal was three times greater than that of the control animal. Overall, our results indicate that MRI technology can be successfully used to document the development of the pituitary gland in vivo. Application of knowledge gained from this novel approach to study the growth, development and function of endocrine glands over time, and within the same animal, will enhance human and animal endocrine diagnostic procedures.
rely on tissues and glands collected postmortem to address pertinent questions about the endocrine system components, while clinicians routinely use endocrine testing to confirm a diagnosis. These useful methods have limits regarding the study of the ontogeny of endocrine gland development for any one animal. Thus, new technologies have been sought to identify specific periods during which endocrine gland development and perhaps cellular function could be evaluated. Fortunately, the opportunity to monitor the growth and development of endocrine glands in vivo without testing or killing the animal has become possible with the advent of magnetic resonance imaging (MRI) technology (Daniels et al. 1988 , Brown & Semelka 1995 .
Animal biologists and livestock producers are interested in the control of growth and development in young animals. As rate of gain and feed efficiency affect the success of food production systems, many food animal specialists utilize exogenous hormonal therapy (i.e. androgenic and oestrogenic anabolic agents) to increase growth performance of ruminant livestock. The ability of these exogenous steroidal agents to affect synthesis and secretion of growth hormone (GH) by the pituitary gland is of specific practical and clinical relevance.
Zeranol, the active drug in a Ralgro s (Pittman Moore, Terre Haute, IN, USA) is a derivative of resorcyclic acid lactone fermentation product. It is derived by reducing zearalenone, a potent oestrogenic metabolite produced by some Fusarium species. Zeranol is a non-steroidal oestrogen analogue with anabolic properties, which has been used for oestrogen replacement in humans, but is primarily used as an implantable growth stimulant in cattle and sheep to increase average daily gain, pituitary gland size, GH secretion and GH synthesis (Rothenbacher et al. 1975 , Gopinath & Kitts 1984 , French et al. 1994 ). However, when and how oestrogenic compounds enhance GH secretion, and whether the increase in GH secretion coincides with an enlargement of the pituitary gland (i.e. possibly due to larger and/or more GH-secreting cells) remain unclear. Our studies with zeranol-implanted steers demonstrated specific periods of enhanced sensitivity to exogenous GH-releasing hormone (GHRH), the hypothalamic neurohormone that stimulates synthesis and secretion of GH (French et al. 1991) . Additionally, the hormonal effect of zeranol is manifested several weeks after treatment and the growth response is temporally delayed (French et al. 1991) . Therefore, we propose that these periods may be windows of opportunity for the recruitment (i.e. activity, size or number) of GH-producing cells in the pituitary gland, which may be manifested by an increase in the gland's size.
MRI delineates the in vivo intracranial structures (e.g. thalamus, hypothalamus, anterior pituitary and posterior pituitary) in humans and animals. In dogs, the clinical diagnosis of pituitary-dependent hyperadrenocorticism has been confirmed by identifying pituitary tumours which secreted an excessive amount of adrenocorticotropic hormone (ACTH) , Duesberg et al. 1995 . In humans, MRI has been successfully utilized to document normal pituitary gland dimensions and to detect abnormalities in the hypothalamicpituitary axis which result in hypopituitarism and increased sella emptiness (Root et al. 1989 , Argyropoulou et al. 1992 , Marwaha et al. 1992 . Additionally, the posterior pituitary gland emits a high-intensity signal (due to pituicyte lipid content) that is readily visible, thus allowing distinction between the anterior and posterior lobes of the pituitary gland (Root et al. 1989) .
Therefore, the primary objective of this study was to determine whether MRI technology could be utilized to visually document (over time and within the same animal) the effect of zeranol (an oestrogenic anabolic agent) on growth and development of the ovine pituitary gland.
Materials and methods
All animal procedures used in this study were reviewed and approved by Texas A&M University's Institutional Animal Care and Use Committee. In a preliminary study, a single Holstein bull calf was utilized to evaluate the possible effects associated with repositioning the animal between MRI scans and to evaluate the feasibility of using MRI for documentation of pituitary gland growth over time and within the same animal. The calf's pituitary gland was scanned at 30 and 60 days of age using a mobile MRI unit (Mobile Technology, Inc, Houston, TX, USA) with a 0.5 tesla (T), General Electric superconducting magnet (GE Max, General Electric, Milwaukee, WI, USA). Three millimetre thick, non-contrast enhanced, T1weighted (TR 500-600, TE25) sagittal, transverse and dorsal images were obtained for each evaluation. Sagittal images were recorded only when the mesencephalic aqueduct and infundibulum were distinctly visible in the same image. The on-screen cursor allowed measurement of the length, width and height of the pituitary gland. To determine if body position inside the MRI unit would affect the measurements, three successive scans of the pituitary gland were performed when the calf was 30 days of age. Between each of the three scans, the calf was removed from the MRI unit and repositioned prior to the next scan. This procedure allowed three separate measurements to be recorded for each of the three anatomical planes (i.e. sagittal, transverse and dorsal planes). Results from this preliminary study demonstrated that (1) the pituitary gland could be clearly imaged and measured and (2) positioning did not alter the accuracy of measurements.
In the subsequent study, two, 1/2 sibling Suffolk wethers (castrated rams, 4.5 months of age, $23 kg body weight [BW]) were obtained from the Department of Animal Science's Sheep Center. They were confined in a sheltered 10 0 Â 30 0 dry lot throughout the study. Wethers received coastal hay, a balanced commercial ration (16% crude protein) and water ad libitum. Wethers received either a sham-implant (control; n ¼ 1) or a 24 mg zeranol implant (zeranol; n ¼ 1) at day 0 and day 42. A MRI scan was conducted on each wether prior to any treatment to acquire baseline measurements of the pituitary gland. Wethers were scanned at 14-day intervals for a 70-day period. The wethers' feed and water were removed 48 and 24 h before scanning, respectively, to reduce gastrointestinal contents prior to anaesthesia. Anaesthesia was necessary to immobilize the animal during the scan. Pre-anaesthetic medications were glycopyrolate (Robinul-V s , 0.011 mg/kg BW subcutaneously, Fort Dodge Inc, Fort Dodge, IA, USA) followed by xylazine (Rompun s , 0.055 mg/kg BW intramuscularly, Miles Inc, Shawnee Mission, KS, USA). Propofol (Diprivan s , initial intravenous injection was 2-4 mg/kg BW, maintained at an intravenous drip rate of 0.4 mg/kg/min, Zeneca Pharmaceuticals, Wilmington, DE, USA) was administered intravenously to induce anaesthesia, and anaesthesia was maintained with an intravenous propofol drip (0.4 mg/kg/min). During anaesthesia, oxygen was supplemented using a Bain breathing circuit and an endotracheal tube. Blood pressure, pulse rate and respiration rate were constantly monitored.
Three millimetre thick, non-contrast enhanced, T1-weighted (TR 500-600, TE 25) sagittal, transverse and dorsal images of the pituitary glands of each wether were captured (Figures 1-3 ). Sagittal images were recorded only when the mesencephalic aqueduct and infundibulum were distinctly visible in the same sagittal image. The length, width and height of each pituitary gland were determined with the on-screen cursor. The average length, width and height were calculated from measurements taken from each view. These averages allowed calculation of the volume of each pituitary gland using the equation for a prolated spheriod (volume ¼ [4/3(p) (mean length/2 Â mean width/2 Â mean height/2)]). Additionally, laser film MRI images were made to facilitate determination of the pituitary gland area with a computer-digitizing program.
Results
Imaging the calf provided several pieces of information: (1) MRI can demonstrate (over time and within the same animal) the growth of the pituitary gland; (2) the pituitary gland can be imaged in three planes (i.e. sagittal, transverse and dorsal), allowing Laboratory Animals (2007) 41 measurement of length, width and height of the gland, as well as calculation of the area and volume of the gland and (3) repositioning the animal did not alter the ability to image and accurately measure the same regions (planes) of the pituitary gland. Therefore, MRI can successfully document the growth of the pituitary gland in vivo ($18 mm in diameter at 30 days of age). A significant consideration in planning similar studies is that a calf's body size soon approximates the upper weight capacity of the MRI unit.
The data obtained from MRI examinations of the two sheep are reported as a percent change in volume or area, normalized to the size of the pituitary gland at the time of the baseline scan. Using the image from the sagittal plane (Figure 1) , an increase (30.2%) in pituitary gland area was apparent in the zeranol-treated lamb as early as 14 days postimplantation. By 28 days post-implantation, the area increased by 39.7% for the same wether. An increase in area was not detected in the control wether until day 42 postimplantation (29% increase), at which time the pituitary gland area for the zeranoltreated wether had increased by 55.6%. The greatest increase in percent change of the pituitary gland area (as determined from the sagittal plane) occurred at day 70 for the control wether (48.7%) and at day 56 for the zeranol-treated wether (58.7% increase).
Using the image from the transverse plane ( Figure 2) to determine the pituitary gland Laboratory Animals (2007) 41 Figure 1 Sagittal image of a wether's pituitary gland as obtained by a mobile MRI unit with a 0.5 T, superconducting magnet. Sagittal images were recorded only when the mesencephalic aqueduct and infundibulum were distinctly visible in the same image. The sagittal image allowed for the determination of the height (line 1) and the length (line 2) of the pituitary gland. Pituitary glands were imaged at 14-day intervals for 70 days to determine if and when the anabolic effects of zeranol on pituitary gland growth could be visualized using MRI area, neither the control nor the zeranoltreated wether appeared to have a substantial increase in area until the day 42 scan. At that timepoint, the percent increase in the pituitary gland area was 37.7% for the zeranol-treated wether and 15.3% for the control wether. Additionally, the day 42 scan showed the maximal increase in area for the control wether, whereas the maximal increase in area for the zeranol-treated wether occurred at the day 56 scan (52.2%).
Using the image from the dorsal plane (Figure 3) , the first detectable increase in the pituitary gland area occurred at 14 days postimplantation; the increases in area continued throughout the study for both control and zeranol-treated wethers. At the day 14 scan, the percent increase in pituitary gland size was approximately 4.6-fold greater for the zeranol-treated wether than for the control wether (50% and 10.8%, respectively). The maximum increase in the area of the pituitary gland occurred at day 42 and day 70 for the zeranol-treated and control wethers, respectively. At the day 42 scan, the area increased by 97.2% for the zeranol-treated wether, whereas the area increased by only 39% for the control wether at the day 70 scan.
By obtaining images of the pituitary gland in three anatomical planes (i.e. sagittal, transverse and dorsal), the length, width and height could be measured. These measurements were then inserted into the The transverse image allowed for the determination of the width (line 1) and the height (line 2) of the pituitary gland. Pituitary glands were imaged at 14-day intervals for 70 days to determine if and when the anabolic effects of zeranol on pituitary gland growth could be visualized using MRI equation for a prolated spheroid to determine the volume of the pituitary gland. Over the 70-day period, an increase in pituitary gland volume was detected in both the control and zeranol-treated wethers (Figure 4 ). The differences in percent increase in pituitary gland volume were apparent by 14 days post-implantation (control ¼ 11% versus zeranol ¼ 55%). The overall increase in pituitary gland volume (day 0 versus day 70) was three-fold greater in the zeranol-treated wether as compared with the control wether, 150% versus 50%, respectively.
Discussion
The primary objective was to determine whether MRI could be utilized to visually document (over time and within the same animal) the effect of zeranol (Ralgro s ; an oestrogenic anabolic agent) on growth and development of the pituitary gland in wethers. The results demonstrate that: (1) MRI can reveal an increase in area of the pituitary gland, as visualized in three anatomic planes (i.e. sagittal, transverse and dorsal); (2) calculations based on the MRI measurements can be used to quantitate an increase in the volume of the pituitary gland and (3) MRI can provide visual evidence of alterations in pituitary gland size induced by an oestrogenic anabolic agent. Also, this study showed the importance of obtaining images from at least two of the three anatomic planes for precise representation of the growth of the pituitary gland in vivo.
Laboratory Animals ( When measuring the pituitary gland in the sagittal plane, the overall length and height of the gland could be determined. To calculate the volume of the pituitary gland, an additional measurement (i.e. width of the pituitary gland) was necessary. Both the transverse and dorsal planes provided a measurement for the width of the pituitary gland. The transverse plane allowed the measurements for height and width of the pituitary gland, whereas the dorsal plane measurement revealed the length and the width of the pituitary gland. When more than one anatomic plane produced a measurement for the same parameter (i.e. width), an average was taken.
Over the 70-day study period, average length, width and height of the pituitary gland for the control wether increased from 11.2 to 13.6 mm, 9.7 to 11.4 mm and 7.9 to 9.4 mm, respectively. Average length, width and height of the pituitary gland for the zeranol-treated wether increased from 9.2 to 13 mm, 8.9 to 11.5 mm and 7.3 to 9.7 mm, respectively. These dimensions of the ovine pituitary gland are similar to those reported in human studies which used MRI to evaluate pituitary gland development and GH deficiency (Argyropoulou et al. 1992 , Marwaha et al. 1992 . For example, pituitary gland height ranged from 3 to 7.5 mm in normal age-matched children and young adults (5-20 years of age) (Marwaha et al. 1992) . In a similar human study, pituitary gland height averaged 3.570.2 mm in subjects ranging in age from 15 days to 20 years (Argyropoulou et al. 1992) .
Measurement of the different anatomic planes revealed varying degrees of increase in pituitary gland area. The area obtained from images captured in the sagittal plane represented the length and height of the pituitary gland. The increase in pituitary gland area as determined from the sagittal view demonstrated that early growth of the gland is easily detected by this view, especially in zeranol-treated wethers. This same initial increase in area was also detected from analysis of images from the dorsal view which represents the length and width of the gland. Interestingly, this initial increase in pituitary gland size was not evident on images generated from the transverse plane. The transverse image allows measurement of height and width of the pituitary gland. Therefore, by the process of elimination of parameters, initial growth in the pituitary gland of the zeranol-treated wether occurred due to an increase in length. However, in the sagittal view, there was a plateau, with regard to an increase in pituitary gland area, from day 42 through day 70 of the study.
Relying on only one anatomic plane (i.e. transverse) to detect an increase in pituitary gland size over time could be misleading. This becomes apparent by viewing results obtained from both the transverse and dorsal planes. In each instance, continued growth of the pituitary gland in the zeranol-treated wether was apparent from day 42 through day 70. A shortcoming of obtaining only the transverse image is apparent by the failure to detect the increase in pituitary gland size from the beginning of the study through day 28. Thus, the dorsal image which represents the length and the width of the pituitary gland may be the single most important Figure 4 Percent increase in pituitary gland volume over the 70-day study period. Pituitary gland volume was determined by using the average length, width and height of the pituitary gland obtained from the three separate anatomical planes (i.e. sagittal, transverse and dorsal). These measurements were used in the equation for a prolated spheroid to determine the volume of the pituitary gland. Beginning at day 14 and continuing throughout the 70-day study, an increase in pituitary gland volume was apparent for both the control (&) and zeranoltreated () wether, albeit the increase was greater for the zeranol-treated wether anatomic plane with regard to detecting continuous growth of the ovine pituitary gland. Additionally, height seems to be the least varying parameter associated with pituitary gland growth. The feasibility of using MRI to monitor pituitary gland growth over time and within the same animal was demonstrated by data derived from the control and the zeranoltreated sheep of this study. In consideration of detrimental effects of feed restriction and stress, a concomitant assessment of GH secretion and average daily gain was not performed (Gluckman & Breier 1987 , Thompson et al. 1995 . Subsequent studies can use this foundation information to temporally link structure (MRI images) and functional (GH secretion, average daily gain) changes of the pituitary gland.
The findings from this study, utilizing MRI, coupled with other endocrine physiology procedures will facilitate identification of whether, when and how peptide, nonpeptide and steroidal anabolic agents increase the synthesis and secretion of GH. Technologies such as MRI which allow visual documentation of in vivo pituitary gland growth, as well as growth, development and function of other intracranial structures (i.e. thalamus, hypothalamus, pineal gland, etc.) will undoubtedly enhance not only diagnostic procedures used for humans and animals, but will provide a novel approach for endocrinologists and physiologists to identify and understand the growth, development and function of endocrine glands over time and within the same animal.
